PL1861116T3 - Formulacje antagonistów VEGF - Google Patents

Formulacje antagonistów VEGF

Info

Publication number
PL1861116T3
PL1861116T3 PL06748594T PL06748594T PL1861116T3 PL 1861116 T3 PL1861116 T3 PL 1861116T3 PL 06748594 T PL06748594 T PL 06748594T PL 06748594 T PL06748594 T PL 06748594T PL 1861116 T3 PL1861116 T3 PL 1861116T3
Authority
PL
Poland
Prior art keywords
vegf antagonist
antagonist formulations
formulations
vegf
antagonist
Prior art date
Application number
PL06748594T
Other languages
English (en)
Inventor
Daniel Dix
Kelly Frye
Susan Kautz
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36678320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1861116(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL1861116T3 publication Critical patent/PL1861116T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL06748594T 2005-03-25 2006-03-22 Formulacje antagonistów VEGF PL1861116T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66512505P 2005-03-25 2005-03-25
PCT/US2006/010600 WO2006104852A2 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations
EP06748594.6A EP1861116B1 (en) 2005-03-25 2006-03-22 Vegf antagonist formulations

Publications (1)

Publication Number Publication Date
PL1861116T3 true PL1861116T3 (pl) 2016-02-29

Family

ID=36678320

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13152402T PL2586459T3 (pl) 2005-03-25 2006-03-22 Formulacje antagonistów vegf
PL06748594T PL1861116T3 (pl) 2005-03-25 2006-03-22 Formulacje antagonistów VEGF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13152402T PL2586459T3 (pl) 2005-03-25 2006-03-22 Formulacje antagonistów vegf

Country Status (19)

Country Link
US (16) US20060217311A1 (pl)
EP (3) EP2586459B1 (pl)
JP (2) JP5376573B2 (pl)
KR (1) KR101327270B1 (pl)
CN (2) CN102614134B (pl)
AU (1) AU2006229930C1 (pl)
CA (3) CA3142945A1 (pl)
CY (2) CY1116980T1 (pl)
DK (2) DK1861116T3 (pl)
ES (2) ES2633574T3 (pl)
HU (2) HUE034109T2 (pl)
IL (2) IL185606A (pl)
LT (1) LT2586459T (pl)
NZ (1) NZ560713A (pl)
PL (2) PL2586459T3 (pl)
PT (2) PT1861116E (pl)
SI (2) SI2586459T1 (pl)
WO (1) WO2006104852A2 (pl)
ZA (1) ZA200708845B (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
SI2944306T1 (sl) * 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
AU2012202859C1 (en) * 2006-06-16 2025-08-07 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
MX359570B (es) * 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
CN102552875B (zh) * 2010-12-09 2015-05-20 上海国健生物技术研究院 一种双功能vegf受体融合蛋白制剂
CN103533950A (zh) 2011-01-13 2014-01-22 瑞泽恩制药公司 Vegf拮抗剂在治疗血管生成眼病中的用途
US10864158B2 (en) * 2011-04-14 2020-12-15 The Regents Of The University Of California Multilayer thin film drug delivery device and methods of making and using the same
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
KR102213535B1 (ko) * 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
AR092325A1 (es) * 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
CA2888281A1 (en) * 2012-08-02 2014-02-06 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CN103110105A (zh) * 2012-11-14 2013-05-22 江苏江山制药有限公司 食品添加剂无糖维生素c钠盐颗粒的生产方法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016008975A1 (en) 2014-07-18 2016-01-21 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CN104940926B (zh) * 2014-09-25 2017-09-22 信达生物制药(苏州)有限公司 重组融合蛋白制剂
CN105435222B (zh) 2014-09-25 2018-05-29 信达生物制药(苏州)有限公司 重组融合蛋白制剂
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
AU2016210918A1 (en) 2015-01-28 2017-07-13 Pfizer Inc., Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
IL310367A (en) 2016-10-07 2024-03-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
CA3043487A1 (en) * 2016-11-21 2018-05-24 Just-Evotec Biologics Inc Aflibercept formulations and uses thereof
USD849856S1 (en) 2017-06-28 2019-05-28 Jumpsport, Inc. Standing platform
PL3639845T3 (pl) * 2017-07-25 2023-10-23 Jiangsu Hengrui Medicine Co., Ltd. Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
MA50908A (fr) 2017-11-17 2020-09-23 Amgen Inc Formulations de protéines de fusion vegfr-fc
WO2019099965A1 (en) 2017-11-20 2019-05-23 Just Biotherapeutics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
AU2018375398C1 (en) 2017-11-30 2026-01-15 Regeneron Pharmaceuticals, Inc. Use of a VEGF antagonist to treat angiogenic eye disorders
EP3730126B1 (en) * 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
JP7235770B2 (ja) * 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021050687A1 (en) 2019-09-10 2021-03-18 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020393842A1 (en) 2019-11-25 2022-06-16 The Regents Of The University Of California Long-acting VEGF inhibitors for intraocular neovascularization
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
KR102337471B1 (ko) * 2019-12-23 2021-12-09 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
KR20220015976A (ko) * 2020-07-31 2022-02-08 (주)셀트리온 안정한 약제학적 제제
CN120204358A (zh) * 2023-12-27 2025-06-27 成都康弘生物科技有限公司 一种含有抗vegf的融合蛋白的药物组合物
WO2025227916A1 (zh) 2024-04-29 2025-11-06 齐鲁制药有限公司 包含阿柏西普和其变体的组合物以及相关方法和应用
US12240888B1 (en) 2024-04-29 2025-03-04 QILU Pharmaceutical, Co., Ltd. Composition comprising aflibercept and a variant thereof, and related methods and uses

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
DE69333928T2 (de) * 1992-04-30 2006-08-17 Probitas Pharma Inc., Los Angeles Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
JPH09154588A (ja) * 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
JPH10273450A (ja) 1997-03-27 1998-10-13 Toagosei Co Ltd 眼内血管新生性疾患治療薬
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1180024A (ja) 1997-09-12 1999-03-23 Toagosei Co Ltd 角膜血管新生阻害剤
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
WO2000063380A1 (en) 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
MXPA01012630A (es) 1999-06-08 2002-07-22 Regeneron Pharma Polipeptidos quimericos modificados con propiedades farmacocineticas mejoradas.
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7001892B1 (en) * 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
AU2002324556A1 (en) * 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
ATE354592T1 (de) * 2003-03-28 2007-03-15 Regeneron Pharma Vegf-antagonisten zur behandlung von diabetes
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
MXPA05008973A (es) 2003-05-28 2006-02-22 Regeneron Pharma Metodo de tratamiento de rechazo de trasplante de cornea.
CA2519875C (en) 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
ITMI20031261A1 (it) 2003-06-20 2004-12-21 Messersi Packaging Srl Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia.
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US20050112061A1 (en) 2003-08-06 2005-05-26 Jocelyn Holash Use of a VEGF antagonist in combination with radiation therapy
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
ATE507240T1 (de) 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
EP1740168A2 (en) 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandins for the treatment of ocular pathologies
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
PL1767546T3 (pl) 2004-06-08 2012-07-31 Chengdu Kanghong Biotechnologies Co Ltd Hamujące angiogenezę białka chimeryczne i ich zastosowanie
CN1304427C (zh) 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
CA2567686A1 (en) 2004-06-10 2005-12-29 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for the treatment of human cancer
CN1968709A (zh) 2004-06-18 2007-05-23 瑞泽恩制药公司 用于治疗恶性胸腔积液的vegf抑制剂
AU2005267741A1 (en) 2004-07-30 2006-02-09 Regeneron Pharmaceuticals, Inc. Methods of treating type I diabetes by blocking VEGF-mediated activity
EP1802334B1 (en) 2004-10-21 2012-08-29 Genentech, Inc. Method for treating intraocular neovascular diseases
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100567325C (zh) 2006-03-31 2009-12-09 成都康弘生物科技有限公司 Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
CN102233132B (zh) 2010-04-28 2013-10-23 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用
CN102380096B (zh) 2010-08-31 2014-04-30 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
CN103212075B (zh) 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
DE202013000688U1 (de) 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
NZ721607A (en) 2014-01-25 2017-05-26 Chengdu Kanghong Biotechnologies Co Ltd Fusion protein inhibiting angiogenesis or growth and use thereof
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
EP3195874A1 (en) 2017-07-26
US8110546B2 (en) 2012-02-07
US10406226B2 (en) 2019-09-10
US20150079087A1 (en) 2015-03-19
US20170360930A1 (en) 2017-12-21
AU2006229930B2 (en) 2010-08-05
JP2008535819A (ja) 2008-09-04
PT1861116E (pt) 2015-11-04
CA3142945A1 (en) 2006-10-05
US20210393778A1 (en) 2021-12-23
US9416167B2 (en) 2016-08-16
ZA200708845B (en) 2010-07-28
JP2013079270A (ja) 2013-05-02
PT2586459T (pt) 2017-07-25
US20190388539A1 (en) 2019-12-26
EP2586459A1 (en) 2013-05-01
CY1116980T1 (el) 2017-04-05
AU2006229930A1 (en) 2006-10-05
KR20080015780A (ko) 2008-02-20
US20160175439A1 (en) 2016-06-23
US20120101035A1 (en) 2012-04-26
CA2995971A1 (en) 2006-10-05
US20060217311A1 (en) 2006-09-28
US8710004B2 (en) 2014-04-29
AU2006229930C1 (en) 2013-07-25
DK2586459T3 (en) 2017-09-11
WO2006104852A2 (en) 2006-10-05
HUE034109T2 (en) 2018-01-29
US11806398B2 (en) 2023-11-07
KR101327270B1 (ko) 2013-11-08
IL227215A (en) 2016-02-29
EP2586459B1 (en) 2017-05-24
US10857231B2 (en) 2020-12-08
US20210393530A1 (en) 2021-12-23
US20210252147A1 (en) 2021-08-19
US20210252105A1 (en) 2021-08-19
PL2586459T3 (pl) 2017-12-29
US9511140B2 (en) 2016-12-06
US20170073407A1 (en) 2017-03-16
CA2598711A1 (en) 2006-10-05
US9636400B2 (en) 2017-05-02
US8404638B2 (en) 2013-03-26
JP5376573B2 (ja) 2013-12-25
US20130261056A1 (en) 2013-10-03
JP5752671B2 (ja) 2015-07-22
CN102614134B (zh) 2016-09-07
EP1861116A2 (en) 2007-12-05
ES2548238T3 (es) 2015-10-15
HUE027096T2 (en) 2016-08-29
CN102614134A (zh) 2012-08-01
HK1116050A1 (en) 2008-12-19
CN101141975A (zh) 2008-03-12
US20100279933A1 (en) 2010-11-04
LT2586459T (lt) 2017-09-25
US20120178683A1 (en) 2012-07-12
IL185606A0 (en) 2008-01-06
ES2633574T3 (es) 2017-09-22
CY1119243T1 (el) 2018-02-14
SI2586459T1 (sl) 2017-10-30
SI1861116T1 (sl) 2015-12-31
WO2006104852A3 (en) 2007-02-01
EP1861116B1 (en) 2015-09-16
US8921316B2 (en) 2014-12-30
IL185606A (en) 2013-08-29
CA2598711C (en) 2018-05-29
NZ560713A (en) 2010-11-26
CN101141975B (zh) 2012-05-23
US20210077624A1 (en) 2021-03-18
DK1861116T3 (en) 2015-11-09
US20160244504A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
IL227215A (en) Vegf antagonists
GB2424581B (en) Formulations
ZA200803811B (en) Neuropolin antagonists
ZA200801773B (en) New formulation
IL185773A0 (en) Formulations
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
TWI370115B (en) New formulation
GB0518652D0 (en) Device
GB0526419D0 (en) Formulation
GB0517673D0 (en) Formulation
ZA200903523B (en) Poly-TLR antagonist
GB0501030D0 (en) Formulation
PL1928232T3 (pl) Stała formulacja
GB0525029D0 (en) Receptor Antagonist
GB0406951D0 (en) Improved formulation
GB0508681D0 (en) Antagonist
GB0516946D0 (en) Receptor
GB0409607D0 (en) Antagonist
GB0520388D0 (en) Formulations
GB0522917D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0526322D0 (en) Formulations
GB0408112D0 (en) Improved formulation
GB0510788D0 (en) Formulation
GB0507811D0 (en) Formulation